相关实验视频

Updated: Jul 6, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

在接受化疗的非霍奇金淋巴瘤患者中,COVID-19复发

António Carujo¹, Luís Ferreira¹, Rui Bergantim^2,3,4

¹Infectious Diseases Department, Santo António University Hospital, Porto, PRT.

|January 5, 2024

概括

淋巴瘤治疗导致B细胞枯竭的患者可能会经历长时间的COVID-19 (冠状病毒病2019) 严重复发. 这一案例突显了持续的SARS-CoV-2感染与治疗期间免疫状况恶化有关.

科学领域:

免疫学免疫学免疫学
病毒学病毒学
在瘤学瘤学.

背景情况:

血液恶性瘤及其治疗,如R-CHOP化疗,显著增加严重COVID-19 (冠状病毒疾病2019) 和死亡率的风险.
免疫功能低下的个体,尤其是B细胞枯竭的个体,容易受到长期的SARS-CoV-2病毒分泌和持续感染.

关键词:

在COVID-19中,有很多人.免疫抑制疗法是一种免疫抑制疗法.淋巴瘤淋巴瘤是什么在R-CHOP协议中,这就是Rituximab.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...